Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter

Clinical Cancer Research

Volumn 2, Issue 6, 1996, Pages 1017-1030

  Begemann, Martin ^a   Kashimawo, Sharafadeen A ^a   Choi, Yu Jeong A ^a   Kim, Susan ^a   Christiansen, Kim M ^a   Duigou, Gregg ^a   Mueller, Marcel ^b   Schieren, Ira ^a   Ghosh, Subrata ^a   Fabbro, Doriano ^b   Lampen, Nina M ^c   Heitjan, Daniel F ^a   Schiff, Peter B ^a   Bruce, Jeffrey N ^a   Weinstein, I Bernard ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b Ciba Geigy ^*  (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 42700; MIDOSTAURIN; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER DERIVATIVE; PROTEIN KINASE C INHIBITOR; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTES; BROMODEOXYURIDINE; CELL CYCLE; ENZYME INHIBITORS; FEMALE; GLIOBLASTOMA; HUMANS; ISOENZYMES; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROTEIN KINASE C; STAUROSPORINE; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 8944239874     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Nishizuka, Y. Studies and perspectives of protein kinase C. Science (Washington DC), 235: 305-312, 1986.
2. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (Lond.), 334: 661-665, 1988.
3. Weinstein, I. B., Borner, C. M, Krauss, R. S., O'Driscoll, K, Choi, P. M., Moritomi, M., Hoshina, S., Hsieh, L-L., Tchou-Wong, K-M., Nichols-Guadagno, S., Ueffing, M., and Guillem, J. Pleiotropic effects of protein kinase C and the concept of carcinogenesis as a progressive disorder in signal transduction. In: J Brugge, T. Curran, E. Harlow, and F. McCormick (eds.), Origins of Human Cancer A Comprehensive Review, pp. 113-124. NY: Cold Spring Harbor Laboratory, 1991.
4. Mousey, G. M., Johnson, M. D., Hsiao, W. W. L., O'Brian, C. A., Murphy, J. P., Kirschmeier, P., and Weinstein, I. B. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell, 52: 343-354, 1988
5. Borner, C., Filipuzzi, I., Weinstein, I. B., and Imber, R. Failure of wild-type or a mutant form of protein kinase C-α to transform fibreblasts. Nature (Lond.), 353: 78-80, 1991.
6. Cacace, A. M., Guadagno, S. N., Krauss, R. S., Fabbro, D., and Weinstein, I. B. The ∈ isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene, 8: 2095-2104, 1993.
7. Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Roesel, J., Mueller, M., Caravatti, G., and Matter, A. A derivative of staurosporine (CGP 41.251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer, 43: 851-856, 1989.
8. Andrejauskas-Buchdunger, E., and Regenass, U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res., 52: 5353-5358, 1992.
9. Marte, B. M., Meyer, T., Stabei, S., Standke, G. J. R., Jaken, S., Fabbro, D., and Hynes, N. E. Protein kinase C and mammary cell differentiation: involvement of protein kinase Cα in the induction of β-casein expression. Cell Growth & Differ., 5: 239-247, 1994.
10. Ausubel, F. A., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds.), Current Protocols in Molecular Biology. New York: Greene & Wiley-Interscience, 1990.
11. Mosmann, T. Rapid colorimetric assay for cellular growth and survival, application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
12. Ponten, J., and Macintyre, E. H. Long-term culture of normal and neoplastic glia. Acta Pathol. Microbiol. Scand., 74: 465-486, 1968.
13. Beckman, G., Beckman, L., Ponten, J., and Westermark, B. G-6-PD and PGM phenotypes of 16 continuous human tumor cell lines. Hum. Hered., 21: 238-241, 1971.
14. Buchdunger, E., Trinks, U., Mett, H., Regenass, U., Mueller, M., Meyer, T., McGlynn, E., Pinn, L. A., Traxler, P., and Lydon, N. B. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA, 91: 2334-2338, 1994.
15. Evans, B D, Smith, I. E., Shorthouse, A. J., and Millar, J. L. A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. Br. J. Cancer. 45: 466-468, 1982.
16. Inoue, M., Kishimoto, A., Takai, Y., and Nishizuka, Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. J. Biol. Chem., 252. 7610-7616, 1977.
17. Sacktor, T. C., Osten, P., Valsamis, H., Jiang, X., Naik, M. U., and Sublette, E. Persistent activation of the ζ isoform of protein kinase C in the maintenance of long-term potentiation Proc. Natl. Acad. Sci. USA, 90: 8342-8346, 1993.
18. Ringertz, N. Grading of gliomas. Acta Pathol. Microbiol. Scand., 27: 51-64, 1950.
19. Black, P. M., Schoene, W. C, and Lampson L. (eds.), Astrocytomas: Diagnosis, Treatment, and Biology. Boston: Blackwell Scientific Publications, 1993.
20. Benzil, D. L., Finkelstein, S. D., Epstein, M. H., and Finch, P. W. Expression pattern of α-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res., 52: 2951-2956, 1992.
21. Baltuch, G. H., Couldwell, W T., Villemure, J-G., and Yong, V. W. Protein kinase C inhibitors suppress cell growth in established and low passage glioma cell lines: a comparison between staurosporine and tamoxifen. Neurosurgery, 33: 495-501, 1993.
22. Couldwell, W., Antel, J. P., and Yong, V. W. Protein kinase C activity correlates with the growth rate of malignant gliomas. Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery, 31: 717-724, 1992.
23. Misra-Press, A., Fields, A. P., Samols, D., and Goldthwait, D. A. Protein kinase C isoforms in human glioblastoma cells. Glia, 6: 188-197, 1992.
24. Ahmad, S., Mineta, T., Martuza, R. L., and Glazer, R. I. Antisense expression of protein kinase Cα inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery, 35: 904-909, 1994.
25. Couldwell, W. T., Uhm, J. H., Antel, J. P., and Yong, V. W. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery, 29: 880-887, 1991.
26. Bhat, N. R. Role of protein kinase C in glial cell proliferation. J. Neurosci. Res., 22: 20-27, 1989.
27. Choi, P. M., Tchou-Wong, K. M., and Weinstein, I. B. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol. Cell. Biol., 70: 4650-4657, 1990.
28. Watanabe, T., Ono, Y., Taniyama, Y., Hazama, K., Igarashi, K., Ogita, K., Kikkawa, U., and Nishizuka, Y. Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-δ sub-species. Proc. Natl. Acad. Sci. USA, 89: 10159-10163, 1992.
29. Arita, Y., O'Driscoll, K. R., and Weinstein, I. B. Growth inhibition of human melanoma-derived cells by 12-O-tetradecanoyl phorbol 13-acetate. Int. J. Cancer, 56: 229-235, 1994.
30. Kennedy, M. J., Prestigiacomo, L. J., Tyler, G., May, W. S., and Davidson, N. E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res., 52: 1278-1283, 1992.
31. Hornung, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
32. Schuchter, L. M., Es, A. H., May, W. S., Laulis, M. K., Pettit, G. R., and Hess, A. D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res., 51: 682-687, 1991.
33. Steube, K. G., and Drexler, H. G. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1. Leukemia Lymphoma, 9: 141-148, 1993.
34. Muleris, M., Almeida, A., Dutrillaux, A. M., Pruchon, E., Vega, F., Delattre, J. Y., Poisson, M., Malfoy, B., and Dutrillaux, B. Oncogene amplification in human gliomas: a molecular cytogenetic analysis. Oncogene, 9: 2717-2722, 1994.
35. Nister, M., Libermann, T A., Betsholtz, C., Pettersson, M., Claesson-Welsh, L., Heldin, C-H., Schessinger, J., and Westermark, B. Expression of mRNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines. Cancer Res., 48: 3910-3918, 1988.
36. Ekstrand, A. J., James, C. D., Cavanee, W. K., Seliger, B., Pettersson, R. F., and Collins, V. P. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo Cancer Res., 51: 2164-2172, 1991.
37. Chaffanet, M., Chauvin, C., Laine, M., Berger, F., Chedin, M., Rost, N., Nissou, M-F., and Benabid, A. L. EGF receptor amplification and expression in human brain tumors. Eur. J. Cancer, 28: 11-17, 1992.
38. Levin, D. E., Fields, F. O., Kunisawa, R., Bishop, J. M., and Thorner, J. A candidate protein kinase C gene, PKC1, is required for the S. cerevisiae cell cycle. Cell, 62: 213-224, 1990.
39. Hayles, J., Fisher, D., Woollard, A., and Nurse, P. Temporal order of S phase and mitosis in fission yeast is determined by the state of the p34cdc2-mitotic B cyclin complex. Cell, 78: 813-822, 1994.
40. Gadbois, D. M., Hamaguchi, J. R., Swank, R. A., and Bradbury, E. M. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem. Biophys. Res. Commun., 184: 80-85, 1992.
41. Th'ng, J. P. H., Guo, X-W., Swank, R. A., Crissman, H. A., and Bradbury, E. M. Inhibition of histone phosphorylation by staurosporine leads to chromosome decondensation. J. Biol. Chem., 269: 9568-9573, 1994.
42. 2 phase and suppresses cdc2 kinase activation through a mechanisms different from that of DNA damaging agents. Biochem. Biophys. Res. Commun., 199: 937-943, 1994.
43. Usui, T., Yoshida, M., Abe, K., Osada, H., Isono, K., and Beppu, T. Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. J. Cell Biol., 115: 1275-1282, 1991.
44. Bruno, S., Ardelt, B., Skierski, J. S., Traganos, F., and Darzynkiewicz, Z. Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res., 51: 470-473, 1992.
45. 1 phase of the cell cycle. Proc. Natl. Acad. Sci. USA, 88: 7580-7584, 1991.
46. McConkey, D. J., Hartzell, P., Jondal, M., and Orrenius, S. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J. Biol. Chem., 264, 13399-13402, 1989.
47. Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., and Raff, M. C. Cell death and control of cell survival in the oligodendrocyte lineage. Cell, 70: 31-46, 1992.
48. Cohen, G. M., Sun, X-M., Snowden, R. T., Dinsdale, D., and Skilleter, D. N. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem. J., 286: 331-334, 1992.
49. Ucker, D S, Obermiller, P. S., Eckhart, W., Apgar, J. R., Berger, N. A., and Meyers, J. Genome digestion is a dispensable consequence of physiological cell death mediated by CTLs. Mol. Cell. Biol., 12: 3060-3069, 1992.
50. Couldwell, W. T., Hinten, D. R., He, S., Chen, T. C., Sebat, I., Weiss, M. H., and Law, R. E. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett., 345: 43-46, 1994.